Antitumor activity of lenvatinib mesilate in human hepatocellular carcinoma preclinical models

被引：0
|
作者：
Matsuki, Masahiro
Yamamoto, Yuji
Hoshi, Taisuke
Kimura, Takayuki
Funahashi, Yasuhiro
Matsui, Junji
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1805
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1805
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Antitumor activity of lenvatinib mesilate (LEN) via angiogenesis inhibition and tumor FGF signaling pathway in the human hepatocellular carcinoma models
    Hoshi, Taisuke
    Matsuki, Masahiro
    Yamamoto, Yuji
    Minoshima, Yukinori
    Matsui, Junji
    Funahashi, Yasuhiro
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [2] Synergistic Effect of Lenvatinib and Chemotherapy in Hepatocellular Carcinoma Using Preclinical Models
    Wang, Mingxun
    Yao, Xinfei
    Bo, Zhiyuan
    Zheng, Jiuyi
    Yu, Haitao
    Xie, Xiaozai
    Lin, Zixia
    Wang, Yi
    Chen, Gang
    Wu, Lijun
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 483 - 495
  • [3] Distinct relationship of antitumor activity of lenvatinib (LEN) and sorafenib (SOR) to FGF21 expression levels in preclinical hepatocellular carcinoma (HCC) models
    Miyano, S. Watanabe
    Taisuke, H.
    Ito, J.
    Kodama, K.
    Watanabe, H.
    Takase, K.
    Matsui, J.
    Funahashi, Y.
    Nomoto, K.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E39 - E39
  • [4] Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
    Kissel, Maria
    Berndt, Sandra
    Fiebig, Lukas
    Kling, Simon
    Ji, Qunsheng
    Gu, Qingyang
    Lang, Tina
    Hafner, Frank-Thorsten
    Teufel, Michael
    Zopf, Dieter
    ONCOTARGET, 2017, 8 (63): : 107096 - 107108
  • [5] Antitumor activity of a combination of lenvatinib mesilate, ifosfamide, and etoposide against human pediatric osteosarcoma cell lines
    Matsuki, Masahiro
    Okamoto, Kiyoshi
    Dezso, Zoltan
    Agoulnik, Sergei I.
    Funahashi, Yasuhiro
    Matsui, Junji
    CANCER RESEARCH, 2016, 76
  • [6] Preclinical human and murine models of hepatocellular carcinoma (HCC)
    Sundi, Pharidah Rajan Ibrahim Omar
    Thipe, Velaphi C.
    Omar, Mohamed Abdullahi
    Adelusi, Temitope Isaac
    Gedefa, Jalene
    Olaoba, Olamide T.
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
  • [7] Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
    Kimura, Takayuki
    Kato, Yu
    Ozawa, Yoichi
    Kodama, Kotaro
    Ito, Junichi
    Ichikawa, Kenji
    Yamada, Kazuhiko
    Hori, Yusaku
    Tabata, Kimiyo
    Takase, Kazuma
    Matsui, Junji
    Funahashi, Yasuhiro
    Nomoto, Kenichi
    CANCER SCIENCE, 2018, 109 (12) : 3993 - 4002
  • [8] Curcumol Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells
    Wu, Zhaoli
    Wang, Jia
    DISCOVERY MEDICINE, 2024, 36 (180) : 199 - 208
  • [9] Antitumor Activity of Acriflavine in Human Hepatocellular Carcinoma Cells
    Lee, Chia-Jen
    Yue, Chia-Herng
    Lin, Yu-Yu
    Wu, Jaw-Ching
    Liu, Jer-Yuh
    ANTICANCER RESEARCH, 2014, 34 (07) : 3549 - 3556
  • [10] Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells
    Hou, Fang-jie
    Guo, Li-xiao
    Zheng, Kai-yan
    Song, Jun-na
    Wang, Qian
    Zheng, Yu-guang
    ONCOTARGETS AND THERAPY, 2019, 12 : 6685 - 6697
12345